Oct 18 (Reuters) – NuCana PLC: * NUCANA PRESENTS ENCOURAGING DATA ON NUC-7738 IN COMBINATION WITH PD-1 INHIBITORS USING PRIMARY PATIENT-DERIVED ORGANOIDS AND AUTOLOGOUS TUMOR-INFILTRATING LYMPHOCYTES AT THE ESMO CONGRESS 2025 * NUCANA PLC – REGULATORS APPROVE STUDY EXPANSION FOR 28 MORE PATIENTS * NUCANA PLC – DATA TO DATE FROM NUTIDE:701 SHOWS FAVORABLE SAFETY AND TUMOR REDUCTION Source text: Further company coverage:
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
SHENZHEN, China, Nov 17 (Reuters) - Chinese leader Xi Jinping is due to meet US…
By Eduardo Baptista and Laurie Chen BEIJING, Nov 17 (Reuters) - Chinese entities are adopting…
SYDNEY, Nov 17 (Reuters) - The Australian dollar weakened to a 10-month low on Tuesday…
WASHINGTON, Nov 16 (Reuters) - The US Commerce and Justice Departments released information on Monday…
By Eduardo Baptista and Laurie Chen BEIJING, Nov 17 (Reuters) - Chinese entities are adopting…
By Eduardo Baptista and Laurie Chen BEIJING, Nov 17 (Reuters) - Chinese entities are adopting…